设计,合成和生物评估C1-烯胺衍生物C1-烯胺衍生物
Su-Mei Wang1, Wan-Sheng Ji2, Long-Jiang Chen3
1Sichuan Engineering Research Center for Biomimetic Synthesis of Natural Drugs, School of Life Science and Engineering, Southwest Jiaotong University, Chengdu 610031, China; School of Chemistry, Southwest Jiaotong University, Chengdu 610031, China.
Fitoterapia
|April 9, 2025
概括
新的胺衍生物在阿尔茨海默病 (AD) 方面显示出有前途. 化合物4k有效地抑制乙胆酶 (AChE) 和丁胆酶 (BChE),同时保护大脑细胞,表明作为多功能AD治疗的潜力.
科学领域:
- 药用化学 医学化学
- 神经科学是一个神经科学.
- 药物发现 药物发现 药物发现
背景情况:
- 阿尔茨海默病 (AD) 构成了重大挑战,需要新的治疗策略.
- 针对阿尔茨海默氏症病理学的各个方面的多功能分子非常受欢迎.
- 加兰他胺衍生物为开发新的抗老年痴呆症药物提供了一个有前途的支架.
研究的目的:
- 设计和合成新型C1-烯胺衍生物.
- 评估这些衍生物的胆酶抑制和神经保护作用.
- 为了确定潜在的多功能药物候选人阿尔茨海默病.
主要方法:
- 一系列C1-烯兰胺衍生物 (4a-x) 的合成.
- 测定胆酶抑制活性对抗电光 (Electrophorus electricus acetylcholinesterase) (EeAChE) 和马 (Equus caballus butyrylcholinesterase) (EqBChE) 的活性.
- 在SH-SY5Y细胞中对过氧化 (H2O2) 诱导的损伤的神经保护的评估.
主要成果:
- 化合物4b和4h分别表现出对EeAChE和EqBChE的选择性抑制.
- 化合物4k对EeAChE和EqBChE都表现出双重抑制活性.
- 包括4k在内的8种衍生品在25μM时显示出显著的神经保护作用.
- 化合物4k显示强大的双胆酶抑制和神经保护.
结论:
- 合成的C1-烯兰他胺衍生物具有有前途的抗阿尔茨海默病特性.
- 化合物4k是一种显著的多功能药物,具有双胆酶抑制和神经保护能力.
- 对4k化合物进行进一步的研究是有必要的,因为它有可能作为阿尔茨海默氏症的治疗方法.
相关概念视频
Structure-Activity Relationships and Drug Design
469
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
469
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
2.5K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
2.5K
Preparation of 1° Amines: Gabriel Synthesis
3.4K
Direct alkylation is not a suitable method for synthesizing amines because it produces polyalkylated products. Gabriel synthesis is the most preferred method to exclusively make primary amines. The method uses phthalimide, which contains a protected form of nitrogen that participates in alkylation only once to predominantly give primary amines.
Strong bases like NaOH or KOH deprotonate the phthalimide to form the corresponding anion, which acts as a nucleophile. Further, the anion attacks an...
Strong bases like NaOH or KOH deprotonate the phthalimide to form the corresponding anion, which acts as a nucleophile. Further, the anion attacks an...
3.4K
Preparation of 1° Amines: Hofmann and Curtius Rearrangement Overview
3.1K
In the presence of an aqueous base and a halogen, primary amides can lose the carbonyl (as carbon dioxide) and undergo rearrangement to form primary amines. This reaction, called the Hofmann rearrangement, can produce primary amines (aryl and alkyl) in high yields without contamination by secondary and tertiary amines.
3.1K
Alzheimer's Disease: Treatment
137
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
137
Parkinson's Disease: Treatment
166
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
166


![Technical Aspect of the Automated Synthesis and Real-Time Kinetic Evaluation of [11C]SNAP-7941](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F59557.jpg&w=3840&q=50)